George Yancopoulos, Board Co-Chair, President, and Chief Scientific Officer of Regeneron Pharmaceuticals (REGN), has demonstrated a clear selling bias in recent transactions, with no recorded buys in his last 19 trades. Since May 2024, Yancopoulos has executed multiple sales of REGN shares, including a concentrated sell-off on May 16 totaling approximately $36.4 million across 11 transactions, with individual sales ranging from $768,053 to $9.2 million. The activity continued into December 2025, with two major dispositions: a $92.5 million sale on December 9 and a $22 million sale on December 31.
Over his entire filing history, Yancopoulos has traded only Regeneron stock, with total sales of $360.2 million outweighing purchases of $150.6 million—a 2.4-to-1 ratio favoring dispositions. The recent absence of buy transactions, coupled with high-value sales, suggests a sustained reduction in his REGN holdings. Notably, the December 2025 transactions included derivative dispositions (code "F") and market sales (code "S"), with the $81.6 million December 9 trade marked as an open-market sale (code "M"). The pattern reflects a consistent divestment strategy without offsetting acquisitions in the reported period.
AI-assisted summary